Medicenna Therapeutics Corp.
MDNAF
$0.56
$0.012.01%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.11M | 989.60K | 941.00K | 853.60K | 1.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.03M | 3.97M | 3.98M | 3.98M | 3.66M |
| Operating Income | -4.03M | -3.97M | -3.98M | -3.98M | -3.66M |
| Income Before Tax | -3.13M | -3.55M | -3.56M | 827.10K | -3.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.13M | -3.55M | -3.56M | 827.10K | -3.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.13M | -3.55M | -3.56M | 827.10K | -3.71M |
| EBIT | -4.03M | -3.97M | -3.98M | -3.98M | -3.66M |
| EBITDA | -4.03M | -3.97M | -3.97M | -3.98M | -3.64M |
| EPS Basic | -0.04 | -0.04 | -0.04 | 0.01 | -0.05 |
| Normalized Basic EPS | -0.02 | -0.03 | -0.03 | 0.01 | -0.03 |
| EPS Diluted | -0.04 | -0.04 | -0.04 | 0.01 | -0.05 |
| Normalized Diluted EPS | -0.02 | -0.03 | -0.03 | 0.01 | -0.03 |
| Average Basic Shares Outstanding | 83.42M | 83.41M | 82.52M | 78.19M | 78.01M |
| Average Diluted Shares Outstanding | 83.42M | 83.41M | 82.52M | 78.19M | 78.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |